HL 237
Alternative Names: HL237Latest Information Update: 02 Oct 2021
At a glance
- Originator Hanlim Pharmaceutical
- Class Antirheumatics; Biguanides
- Mechanism of Action STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rheumatoid arthritis
Most Recent Events
- 18 Nov 2020 Phase-I development in Rheumatoid arthritis (In volunteers) in South Korea is ongoing (PO, Tablet) (NCT03896594)
- 18 Nov 2020 Hanlim Pharmaceutical completes enrolment in a phase I pharmacokinetic trial (In adults, In volunteers) in South Korea (PO), prior to November 2020 (NCT04633733)
- 10 Sep 2020 Phase-II clinical trials in Rheumatoid arthritis in South Korea (PO) (NCT04638426)